Literature DB >> 26147692

Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.

Bram Dorresteijn1, Maarten Rotman2,3, Dorien Faber1, Ruud Schravesande1, Ernst Suidgeest2, Louise van der Weerd2,3, Silvère M van der Maarel3, Cornelis T Verrips1,4, Mohamed El Khattabi1,4.   

Abstract

UNLABELLED: Accumulation and aggregation of the amyloid-β (Aβ) peptide is associated with Alzheimer's disease (AD). Aβ is generated from the amyloid precursor protein by the successive action of two membrane-associated processing enzymes: β-secretase or β-site of amyloid precursor protein cleaving enzyme 1 (BACE1) and γ-secretase. Inhibition of one or both of these enzymes prevents Aβ generation and the accompanying Aβ accumulation. Antigen binding fragments from camelid heavy chain only antibodies (VHHs) were found to exert excellent enzyme inhibition activity. In the present study, we generated VHHs against BACE1 by active immunization of Lama glama with the recombinant BACE1 protein. Two classes of VHHs were selected from a VHH-phage display library by competitive elution with a peptide encoding the Swedish mutation variant of the BACE1 processing site. One VHH was found to inhibit the enzyme activity of BACE1 in vitro and in cell culture, whereas two other VHHs were found to stimulate BACE1 activity under the same conditions in vitro. Furthermore, an in vivo study with a transgenic AD mouse model, using intracisternal injection of the inhibitory VHH, led to acute reduction of the Aβ load in the blood and brain. This inhibitory VHH may be considered as a candidate molecule for a therapy directed towards reduction of Aβ load and prevention of AD progression. Both the inhibitory and stimulatory VHH may be useful for improving our understanding of the structure-function relationship of BACE1, as well as its role in AD progression. DATABASE: The GenBank sequence accession numbers are KR363186 for VHH B1a; KR363187 for VHH B3a; and KR363188 for VHH B5a.
© 2015 FEBS.

Entities:  

Keywords:  Alzheimer's disease; BACE1; VHH; amyloid-β; llama antibody

Mesh:

Substances:

Year:  2015        PMID: 26147692     DOI: 10.1111/febs.13367

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  5 in total

Review 1.  Exploring cellular biochemistry with nanobodies.

Authors:  Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

2.  Non-Invasive Imaging of Amyloid Deposits in a Mouse Model of AGel Using 99mTc-Modified Nanobodies and SPECT/CT.

Authors:  Adriaan Verhelle; Wouter Van Overbeke; Cindy Peleman; Rebecca De Smet; Olivier Zwaenepoel; Tony Lahoutte; Jo Van Dorpe; Nick Devoogdt; Jan Gettemans
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

3.  Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome.

Authors:  Fiorenza Stagni; Alessandra Raspanti; Andrea Giacomini; Sandra Guidi; Marco Emili; Elisabetta Ciani; Alessandro Giuliani; Andrea Bighinati; Laura Calzà; Jacopo Magistretti; Renata Bartesaghi
Journal:  Neurobiol Dis       Date:  2017-03-28       Impact factor: 5.996

4.  AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model.

Authors:  Marika Marino; Lujia Zhou; Melvin Y Rincon; Zsuzsanna Callaerts-Vegh; Jens Verhaert; Jérôme Wahis; Eline Creemers; Lidia Yshii; Keimpe Wierda; Takashi Saito; Catherine Marneffe; Iryna Voytyuk; Yessica Wouters; Maarten Dewilde; Sandra I Duqué; Cécile Vincke; Yona Levites; Todd E Golde; Takaomi C Saido; Serge Muyldermans; Adrian Liston; Bart De Strooper; Matthew G Holt
Journal:  EMBO Mol Med       Date:  2022-03-30       Impact factor: 12.137

5.  Targeting APP/AICD in Down syndrome.

Authors:  Sandra Guidi; Fiorenza Stagni; Renata Bartesaghi
Journal:  Oncotarget       Date:  2017-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.